LON:AVCT - Avacta Group Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 28.11 -0.39 (-1.37 %) (As of 05/22/2019 07:22 AM ET)Previous CloseGBX 28.50Today's RangeGBX 28.10 - GBX 28.9052-Week RangeGBX 21 - GBX 51Volume13,792 shsAverage Volume19,964 shsMarket Capitalization£31.74 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. It operates through two segments, Life Sciences and Animal Health. The company's custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development. In addition, it provides tools and contract services to assist the diagnosis of conditions in animals to enable treatment for veterinarians. The company has a collaboration, licensing, and option agreement with Moderna Therapeutics; research collaboration with OncoSec Medical Incorporated for gene delivery of therapeutic Affimers; and a co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom. Receive AVCT News and Ratings via Email Sign-up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Medical Devices Sub-IndustryN/A SectorMedical Current SymbolLON:AVCT Previous Symbol CUSIPN/A CIKN/A Webhttp://www.avacta.com/ Phone+44-1904-217070Debt Debt-to-Equity RatioN/A Current Ratio4.09 Quick Ratio4.04Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£2.27 million Price / Sales13.99 Cash FlowGBX 11.04 per share Price / Cash Flow2.55 Book ValueGBX 25.20 per share Price / Book1.12Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees114 Outstanding Shares112,926,000Market Cap£31.74 million Next Earnings DateN/A OptionableNot Optionable Avacta Group (LON:AVCT) Frequently Asked Questions What is Avacta Group's stock symbol? Avacta Group trades on the London Stock Exchange (LON) under the ticker symbol "AVCT." How were Avacta Group's earnings last quarter? Avacta Group Plc (LON:AVCT) released its quarterly earnings data on Tuesday, April, 9th. The biotechnology company reported ($4.80) EPS for the quarter. View Avacta Group's Earnings History. Has Avacta Group been receiving favorable news coverage? Media coverage about AVCT stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Avacta Group earned a coverage optimism score of 1.4 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. Who are some of Avacta Group's key competitors? Some companies that are related to Avacta Group include Titan Medical (TMD), Advanced Oncotherapy (AVO), Cyclopharm (CYC), Helius Medical Technologies (HSM), Kromek Group (KMK), Impedimed (IPD), REVA Medical (RVA), Resonance Health (RHT), Protech Home Medical (PHM), Osprey Medical (OSP), Electromed (ELMD), Universal Biosensors (UBI), Surgical Innovations Group (SUN), LBT Innovations (LBT) and Oventus Medical (OVN). What other stocks do shareholders of Avacta Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avacta Group investors own include Skinbiotherapeutics (SBTX), Augean (AUG), 7Digital Group (7DIG), Bunzl (BNZL), ReNeuron Group (RENE), Digital Globe Services (DGS), Countrywide (CWD), Communisis (CMS), Bahamas Petroleum (BPC) and Best of the Best (BOTB). Who are Avacta Group's key executives? Avacta Group's management team includes the folowing people: Prof. Alastair Smith, CEO & Exec. DirectorMr. Tony Gardiner, CFO, Company Sec. & Exec. Director (Age 48)Dr. Michael Albin, AdviserDr. Matt Johnson, Chief Technology OfficerDr. Amrik Basran Ph.D., Chief Scientific Officer How do I buy shares of Avacta Group? Shares of AVCT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Avacta Group's stock price today? One share of AVCT stock can currently be purchased for approximately GBX 28.11. How big of a company is Avacta Group? Avacta Group has a market capitalization of £31.74 million and generates £2.27 million in revenue each year. Avacta Group employs 114 workers across the globe. What is Avacta Group's official website? The official website for Avacta Group is http://www.avacta.com/. How can I contact Avacta Group? Avacta Group's mailing address is Unit 20, Ash Way, WETHERBY, LS23 7FA, United Kingdom. The biotechnology company can be reached via phone at +44-1904-217070. MarketBeat Community Rating for Avacta Group (LON AVCT)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 197 (Vote Outperform)Underperform Votes: 180 (Vote Underperform)Total Votes: 377MarketBeat's community ratings are surveys of what our community members think about Avacta Group and other stocks. Vote "Outperform" if you believe AVCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVCT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: The mechanics of the bid-ask spread in trading Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.